Skip to main content

Table 1 Baseline a characteristics

From: Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs

Characteristics

Oral nonbiologic DMARD patients

MTX patients

Biologic DMARD patients

 

N = 1,698

N = 1,217

N = 3,263

Demographics

   

Age, mean (SD)

49.8 (12.5)

49.8 (12.3)

49.4 (11.6)

Female, number (%)

927 (54.6)

657 (54.0)

1,736 (53.2)

Combination of treatment with another nonbiologic DMARD and/or oral corticosteriod at the index date

168 (9.9)

138 (11.3)

1,512 (46.3)

During the 6-month pre-index period, including the index date

   

Specialist encounter, number (%)

   

Rheumatologist or Dermatologist

1,175 (69.2)

841 (12.3)

2,347 (71.9)

Rheumatologist

1,055 (62.1)

755 (62.0)

2,008 (61.5)

Dermatologist

384 (22.6)

271 (22.3)

896 (27.5)

During the 6-month pre-index period

   

Comorbiditiesb,c, number (%)

   

Hypertension

364 (21.4)

260 (21.4)

670 (20.5)

Diabetes

175 (10.3)

129 (10.6)

376 (11.5)

Hypothyroidism

114 (6.7)

81 (6.7)

200 (6.1)

Chronic pulmonary disease

111 (6.5)

72 (5.9)

176 (5.4)

Deficiency anemia

77 (4.5)

62 (5.1)

164 (5.0)

Psoriasis

545 (32.1)

420 (34.5)

1,194 (36.6)

Charlson comorbidity index, mean (SD)

0.47 (0.87)

0.44 (0.84)

0.52 (0.88)

Prior use of NSAID, oral corticosteriod, and nonbiologic DMARDs, number (%)

   

NSAIDs

991 (58.4)

701 (57.6)

1,665 (51.0)

Oral corticosteriods

550 (32.4)

396 (32.5)

1,036 (31.7)

Nonbiologic DMARDs

0 (0.0)

0 (0.0)

1,938 (59.4)

  1. aThe baseline period consisted of the 6-month period prior to the index date. bElixhauser A, Steiner C, Kruzikas D. Comorbidity Software. January 2004. HCUP Methods Series Report #2004-1. Online, February 6, 2004. US Agency for Healthcare Research and Quality: pp 12-15 [16]. c Only mental and physical comorbidities where at least one of the reported cohorts had a prevalence of ≥5% were reported in the table. DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; number, number of patients; NSAID, nonsteroidal anti-inflammatory drug.